ASGCT: Neurogene details new safety measures after young patient's death in AAV gene therapy trial
Six months after a patient died following a high dose of Neurogene’s Rett syndrome gene therapy candidate, the biotech has shared more details about the event and the new safety protocols that are now incorporated into the ongoing trial.
Six months after a patient died following a high dose of Neurogene’s Rett syndrome gene therapy candidate, the biotech has shared more details about the event and the new safety protocols that are now incorporated into the ongoing trial.
